logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2018 – Tepotinib+gefitinib, a promising combination therapy in MET+/EGFR-mutant non-small cell lung cancer

Data from a phase 2 study showed encouraging efficacy and safety results for a new combination regimen in patients with advanced MET+NSCLC